Additionally, there is a significant difference in SLFN12 signature genes between African Americans and Caucasian Americans, which could indicate a course for targeted therapy that could increase SLFN12 expression, which would then further increase or decrease the SLFN12 signature genes in the African American population and lead to better breast cancer survival rates [17]. This evidence concerns the gene SLFN12 and breast carcinoma.